Bristol-Myers Squibb Company (BMY)

US — Healthcare Sector
Peers: ABBV  MRK  GILD  JNJ  LLY  PFE  AMGN  BIIB 

Automate Your Wheel Strategy on BMY

With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BMY
  • Rev/Share 23.4545
  • Book/Share 8.5908
  • PB 5.5666
  • Debt/Equity 2.9466
  • CurrentRatio 1.2789
  • ROIC 0.1085

 

  • MktCap 96991912800.0
  • FreeCF/Share 6.4431
  • PFCF 7.4119
  • PE 17.8626
  • Debt/Assets 0.5544
  • DivYield 0.0642
  • ROE 0.3193

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation BMY Cantor Fitzgerald -- Neutral -- $55 April 22, 2025
Initiation BMY Piper Sandler -- Overweight -- -- April 22, 2025
Upgrade BMY Jefferies Hold Buy -- $70 Dec. 16, 2024
Resumed BMY BofA Securities -- Neutral -- $63 Dec. 10, 2024
Initiation BMY Bernstein -- Market Perform -- $56 Oct. 17, 2024

News

Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
BMY
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Neutral

BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.

Read More
image for news Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
BMY, GILD, JNJ, NVO, PFE, RHHBY, VRTX
Published: July 08, 2025 by: CNBC
Sentiment: Negative

Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.

Read More
image for news Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
2 Wonderful Dividends At Bargain Basement Prices
BMY, REXR
Published: July 07, 2025 by: Seeking Alpha
Sentiment: Positive

Uncertainty creates value opportunities. In this article, I highlight two value stocks trading far below their historical valuations. Both offer dividend yields that are well above historical average and strong growth potential. Both stocks exemplify how investors can secure decent yields and future upside by buying quality companies when market sentiment is overly pessimistic.

Read More
image for news 2 Wonderful Dividends At Bargain Basement Prices
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
BMY
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Will The Decline in Legacy Drugs Pull Down BMY's Top Line?
BMY
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Negative

Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.

Read More
image for news Will The Decline in Legacy Drugs Pull Down BMY's Top Line?
BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
BMY
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Negative

BMY loses 16.3% YTD as pipeline setbacks and generic pressure offset gains from new drug approvals and sales.

Read More
image for news BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
This Once Dominant Dividend Stock May Be About to Come Back to Life in July
BMY
Published: June 26, 2025 by: 24/7 Wall Street
Sentiment: Positive

For income investors seeking a timely value stock to buy on the dip, former dividend darling Bristol-Myers Squibb (NYSE:BMY) may fit the bill as one of the top names to watch in the month of July.

Read More
image for news This Once Dominant Dividend Stock May Be About to Come Back to Life in July
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
BMY
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Neutral

BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.

Read More
image for news Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst
BMY, CI
Published: June 24, 2025 by: Reuters
Sentiment: Negative

Cigna sued Bristol Myers on Tuesday, accusing the drugmaker of violating federal antitrust law by maintaining a monopoly over a blockbuster multiple myeloma drug sold under the brand name Pomalyst.

Read More
image for news Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst
10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June
BBY, BMY, CAG, EQR, ETR, FRT, KEY, KIM, KMI, LYB, MO, O, OKE, PFE, RF, SPG, TFC, UDR, USB, VZ, WMB
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive

Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” — Barron's Weekly. In Barron's, Steven Wieting, strategist at Citi Wealth, noted that a growing dividend is a tangible benefit for shareholders and a hallmark of companies with strong balance sheets. "Nobody can fake a dividend," he said.

Read More
image for news 10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
BMY
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
BMY, PFE
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Neutral

Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.

Read More
image for news Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
BMY
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive

BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.

Read More
image for news BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
BMY Reports Positive Data on Sotyktu From Arthritis Study
BMY
Published: June 12, 2025 by: Zacks Investment Research
Sentiment: Positive

Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.

Read More
image for news BMY Reports Positive Data on Sotyktu From Arthritis Study
Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
BMY, CELG
Published: June 11, 2025 by: Seeking Alpha
Sentiment: Neutral

Bristol-Myers Squibb Company (NYSE:BMY ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 10:00 AM ET Company Participants Adam Lenkowsky - Executive VP & Chief Commercialization Officer Christopher S. Boerner - CEO & Chairman Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Asad Haider All right.

Read More
image for news Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
BMY
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen
ACI, BMY, CMCSA, COP, CVS, CVX, EPD, ET, F, HPQ, MRK, PFE, PRU, T, UNH, UPS, VZ, WBA, XOM
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Positive

Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YCharts 6/6/25 data on Dividends from 78, which hereafter are referred to as the Fortune Return on Leadership Dividend Dogs (FROLD). ReturnOnLeadership is based on four fundamental factors: Connection to Purpose, Strategic Clarity, Leadership Alignment, and Focused Action.

Read More
image for news 5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen
Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
BMY
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?
BMY
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive

Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-commercialization of the latter's investigational bispecific antibody BNT327 across numerous solid tumor types.

Read More
image for news BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?
Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
BMY, BNTX
Published: June 06, 2025 by: Seeking Alpha
Sentiment: Positive

Bristol-Myers Squibb is attractively valued, offers a 5%+ dividend yield, and benefits from a strong oncology pipeline after its BioNTech deal. The $11B BioNTech partnership gives BMY access to BNT327, targeting large cancer markets, with a deal structure that limits BMY's downside risk. BMY's established cash flows, low payout ratio, and current low valuation make it a safer, income-generating pick versus higher-risk, growth-oriented BioNTech.

Read More
image for news Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
Bristol Myers Collaborates With BNTX for Oncology Candidate
BMY, BNTX
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive

BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.

Read More
image for news Bristol Myers Collaborates With BNTX for Oncology Candidate
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
BMY
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive

Bristol Myers Squibb (BMY) closed the most recent trading day at $48.79, moving +1.06% from the previous trading session.

Read More
image for news Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
BMY, BNTX, BPMC, MRK, SNY
Published: June 02, 2025 by: CNBC Television
Sentiment: Neutral

Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.

Read More
image for news Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Bristol Myers Squibb CEO on $11B cancer drug deal with BioNTech
BMY, BNTX
Published: June 02, 2025 by: CNBC Television
Sentiment: Positive

Christopher Boerner, CEO of Bristol Myers Squibb, said Monday that the company's $11 billion cancer drug partnership with BioNTech could be "the next new frontier in the treatment of cancer." The companies will work on transforming outcomes for patients with difficult-to-treat solid tumors, Boerner said.

Read More
image for news Bristol Myers Squibb CEO on $11B cancer drug deal with BioNTech
Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer
BMY, BNTX
Published: June 02, 2025 by: CNBC Television
Sentiment: Positive

Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.

Read More
image for news Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race
BMY, BNTX
Published: June 02, 2025 by: Market Watch
Sentiment: Positive

Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game.

Read More
image for news Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral

MAINZ, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody.

Read More
image for news BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications
BMY
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Bristol Myers' Opdivo SC wins EU approval as the first PD-1 inhibitor for subcutaneous use across multiple solid tumor indications.

Read More
image for news BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications
Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?
BMY
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Negative

BMY slides 20.7% in 3 months despite strong Q1 and raised outlook, as generic pressure and pipeline setbacks weigh on investor sentiment.

Read More
image for news Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?
Bristol-Myers Squibb's Painful Pullback Has Triggered Richer Dividend Story - Upgrade To Buy
BMY
Published: May 28, 2025 by: Seeking Alpha
Sentiment: Neutral

Bristol Myers Squibb's much needed correction has brought the stock back to earth, nearer to its 1Y means while triggering the expanded forward dividend yields. Its dividend investment thesis appears safe as well, as observed in the management's recent payout hike and the still rich cash flows despite the ongoing patent cliff impact. This is on top of the raised FY2025 guidance, given the accelerating Growth Portfolio revenue profile compared to a year ago, thanks to the M&A activities and intensified R&D efforts.

Read More
image for news Bristol-Myers Squibb's Painful Pullback Has Triggered Richer Dividend Story - Upgrade To Buy

About Bristol-Myers Squibb Company (BMY)

  • IPO Date 1972-06-01
  • Website https://www.bms.com
  • Industry Drug Manufacturers - General
  • CEO Christopher S. Boerner
  • Employees 34100

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.